Skip to main content
Company profile
Xencor, Inc. logo

Xencor, Inc.

Pipeline9 assets

  • XmAb819XmAb819 / ENPP3 x CD3 / Bispecific Antibody / Oncology
    Clear Cell Renal Cell Carcinoma (ccRCC)Phase 1ActiveGlobalColorectal Cancer (CRC)Phase 1ActiveGlobalNon-Small Cell Lung Cancer (NSCLC)Phase 1ActiveGlobal
  • XmAb541XmAb541 / CLDN6 x CD3 / Bispecific Antibody / Oncology
    Ovarian CancerPhase 1ActiveGlobalGerm Cell Tumors (GCT)Phase 1ActiveGlobalSolid TumorsPhase 1ActiveGlobal
  • XmAb808XmAb808 / B7-H3 x CD28 / Bispecific Antibody / Oncology
    Prostate Cancer / Solid TumorsPhase 1ActiveGlobal
  • XmAb942XmAb942 / TL1A / Monoclonal Antibody / Immunology
    Ulcerative Colitis (UC)Phase 2ActiveGlobalInflammatory Bowel Disease (IBD)Phase 2ActiveGlobal
  • XmAb412XmAb412 / TL1A x IL23p19 / Bispecific Antibody / Immunology
    Inflammatory Bowel Disease (IBD)Phase 1ActiveGlobal
  • PlamotamabCD20 x CD3 / Bispecific Antibody / Immunology
    Rheumatoid ArthritisPhase 1ActiveGlobal
  • XmAb657XmAb657 / CD19 x CD3 / Bispecific Antibody / Immunology
    Idiopathic Inflammatory MyositisPhase 1ActiveGlobal
  • ObexelimabCD19 x FcγRIIb / Monoclonal Antibody / Immunology
    Autoimmune DiseasesPhase 3ActiveGlobal
  • TobevibartHepatitis B Virus / Monoclonal Antibody / Infectious Disease
    Chronic Hepatitis B / Hepatitis DPhase 3ActiveGlobal

Latest news4 items

All news

Xencor to Present at the 2026 Cantor Global Healthcare Conference

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 2, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare

Xencor Reports Second Quarter 2026 Financial Results

-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week

Presentation / Abstract • Phase 1ESMO oral presentation Fri, Oct 23, 2026

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 -- PASADENA, Calif. --(BUSINESS WIRE)--Jul. 17, 2026-- Xencor, Inc.

Presentation / Abstract • Phase 1ESMO abstract release Sun, Oct 18, 2026, 3:05 PM PDT
Xencor, Inc. • Endpoint Arena